Home > DARE Reviews > Systematic review of bone health in...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer

Review published: 2012.

Bibliographic details: Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA.  Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. Journal of the American Geriatrics Society 2012; 60(9): 1761-1767. [PubMed: 22985145]

Abstract

OBJECTIVES: To review data from randomized controlled trials (RCTs) that evaluate adverse bone outcomes in older women using aromatase inhibitors (AIs) for early-stage hormone receptor-positive breast cancer.

DESIGN: Systematic review.

SETTING: International RCTs referenced in Medline and EMBASE databases through August 1, 2011.

PARTICIPANTS: Postmenopausal women with early-stage hormone receptor-positive breast cancer receiving adjuvant endocrine therapy.

MEASUREMENTS: Fracture rates and changes in bone turnover markers and bone mineral density.

RESULTS: Eleven RCTs were identified. The majority of trials included women with a mean age in the 60s; and women aged 75 and older and 80 and older were excluded from two studies. Fracture rates ranged from 0.9% to 11%, with AIs having a 1.5 times higher risk than tamoxifen or placebo. Fracture data were not systematically collected in many of these trials. In a small subpopulation of women, AIs were associated with higher markers of bone turnover and lower bone density. The relationship between age and fracture was not described.

CONCLUSION: AIs are associated with low bone density and high fracture risk in women with a mean age in their early 60s. There is a paucity of data describing the effect of baseline fracture risk factors, particularly age, and the longer-term effects on bone health in older women. Future research is needed regarding baseline fracture risk, interventions, and long-term effects on bone in this vulnerable population to inform management decisions to optimize AI duration and ensure quality of life after breast cancer.

© 2012, Copyright the Authors Journal compilation © 2012, The American Geriatrics Society.

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2014 University of York.

PMID: 22985145

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...